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Maintaining intracellular redox balance through tightly controlled systems that regulate production 
(pro-oxidants) and scavenging (anti-oxidants) of reactive oxygen species (ROS) is critical for normal 
cell function. In the heart, ROS are produced primarily by mitochondria as a byproduct of electron 
transport and also by extra-mitochondrial enzymes, such as NADPH oxidases (Nox). Multiple 
antioxidants including superoxide dismutase, catalase, glutathione peroxidase and the 
thioredoxin/thioredoxin-reductase systems counterbalance ROS generation, preserving redox 
equilibrium. Disruption in this equilibrium leads to redox stress, of which two main types have been 
defined: oxidative stress and reductive stress. Oxidative stress, characterised by a shift in the 
oxidative:reductive potential to a more oxidative state due to increased ROS production by pro-
oxidant enzymes and/or reduced anti-oxidant defence mechanisms to scavenge excessive ROS, plays 
a physiological role in aging and wound healing, and a pathophysiological role in atherosclerosis, 
hypertension, heart failure and ischemia-reperfusion injury (1). Reductive stress, on the other hand, is 
characterised by an aberrant increase in reducing equivalents, such as reduced glutathione (GSH) and 
reduced nicotinamide adenine dinucleotide phosphate (NADPH), increased activation of antioxidant 
enzymes and reduced pro-oxidant capacity, leading to a shift in the redox balance from an oxidative 
to a reduced state (2). Intuitively one would consider activation of antioxidant systems as being redox-
protective, however, growing evidence indicates that reductive stress may be even more injurious than 
oxidative stress through processes whereby intrinsic cytoprotective defences negatively target the 
exact systems they should protect (3). In the heart, reductive stress has been linked to mitochondrial 
dysfunction, heart failure, myocardial ischemia-reperfusion injury, cardiac hypertrophy and 
cardiomyopathy. These are the exact pathological conditions associated with oxidative stress. How 
then can both an increase in pro-oxidants and an increase in anti-oxidants or reductants lead to the 
same outcome? 
  
In the current issue, Swain et al shed some light on this enigma (4). A novel cardiomyocyte-
specific glutaredoxin 1-reduction-oxidation sensitive (ro) green fluorescent probe (GFP) (Grx1-
roGFP2) was employed to create a unique mouse model where the glutathione redox potential can be 
measured (4). Although redox biosensors have been utilised extensively to label and track reactive 
oxygen species in cell-based systems (5), the novelty of the GRX1-roGFP2 mouse model is that it 
allows for assessment of the redox potential in cardiomyocytes in a dynamic and quantitative manner 
specifically in the mitochondrial and cytoplasmic compartments, in the intact mouse. Advantages of 
the biosensor approach compared with the frequently used fluorescence probe-based strategy relates 
to greater oxidant species specificity and sensitivity, lack of photobleaching and facility to track 
reactive oxygen species spatially.  
 
The powerful biosensor cardiac transgenic model described in the current issue of the journal 
(4) revealed distinct glutathione redox microdomains in the mitochondria and cytoplasm of 
cardiomyocytes. In particular these compartments have unique glutathione redox features, which 
change in basal and stressed conditions. Of major significance and rather surprisingly, the 
mitochondrial matrix of cardiomyocytes exhibit a highly reduced redox potential compared with the 
cytoplasm (4) posing the question why mitochondria would maintain a state of reductive stress 
relative to oxidative stress in the cytoplasm? This may relate to the fact that mitochondria are the most 
redox-active compartment in cells. They possess a rich network of reducing defence systems 
including glutathione peroxidase, which inactivates H2O2 using GSH as a reducing equivalent (6). 
While GSH is produced in the cytoplasm it accumulates in the mitochondrial matrix, where it exists 
primarily in the reduced state, in large part by NADPH produced in the Krebs cycle (7). There is thus 
important cross-talk between the cytoplasmic and mitochondrial matrices, which impacts redox state 
globally and in a compartment-specific manner. Maintaining mitochondrial energetic balance and the 
reductive redox state are critical for normal mitochondrial function (8). This is especially relevant in 
the heart, which requires a continual supply of energy through oxidation-phosphorylation-regulated 
ATP production in mitochondria.  
  
Mitochondrial redox stress is finely tuned and even small changes in the oxido-reductive 
profile promotes mitochondrial dysfunction and impaired cardiac contraction (9). This is highlighted 
in isolated cardiomyocytes from GRX1-roGFP2 mice which when challenged with acute stresses that 
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increase ROS generation (isoprenaline, angiotensin II, hypoxia) exhibit reductive stress in both the 
cytoplasm and the mitochondria, processes that are reversed with reoxygenation (4). On the other 
hand cardiomyocyte exposure to prolonged stimulation resulted in a shift towards a more oxidised 
milieu in the cytoplasm, phenomena also observed in cardiac mitochondria in GRX1-roGFP2 mice 
exposed to chronic cardiac ischemia induced by left anterior descending artery (LAD)-ligation. This 
change in mitochondrial stress from a reductive to an oxidative state likely contributes to myocardial 
remodelling and injury following an ischemic event (4). Together these findings highlight the 
dynamic and labile state of redox stress in the heart, determined in large part by ROS 
compartmentalisation, antioxidant bioavailability and the nature of the stimulus. The physical and 
functional compartmentalization of oxido-reductive phenomena in mitochondria versus cytoplasm 
likely plays an essential role in redox signaling. Localization of ROS in discrete microdomains and 
redoxomes (redox-active endosomes/organelles) where oxidants are produced and where they interact 
with their specific molecular targets is critical for signaling specificity (10).  
 
The concept of reductive stress and cell function is not new. Already in the 1980s, it was 
shown that chemical hypoxia induces hepatocyte swelling, bleb formation, and loss of cell viability 
through reductive stress caused by respiratory inhibition and formation of ‘toxic’ oxygen species (11). 
Increased reductants have also been implicated in reductive repair of protein radicals in an oxidative 
stress environment. In a transgenic mouse model of human cardiomyopathy caused by a mutation in 
the gene encoding αB-crystallin (mutant protein aggregation cardiomyopathy), protein accumulation 
was associated with an increase in the generation of GSH and NADPH, increased activity of anti-
oxidant enzymes and reductive stress (12). This seminal study was amongst the first to demonstrate a 
distinct role for reductive stress in human cardiac disease (12). More recently, this notion has been 
extended to vascular disease in humans where loss of function of glutathione peroxidase-1 (GPX1) 
was found to induce both oxidative and reductive stress, with reductive stress driving S-
glutathionylation of ROS1 tyrosine phosphatase SHP-2 and processes leading to vascular remodelling 
(13). These finding, together with those highlighted in the current issue (4), suggest that it is timely to 
rethink the current dogma that oxidative stress is the major redox contributor to pathological 
processes underlying cardiovascular disease. Despite the extensive experimental and clinical evidence 
demonstrating hyperactivation of ROS-generating oxidases, increased ROS levels, reduced 
antioxidant capacity and increased oxidative stress, we now need to include in the redox paradigm of 
disease, the importance of antioxidant systems that facilitate increased generation of reducing 
equivalents and consequent increased reductive stress. This change in concept will demand a greater 
understanding of the processes that cause a shift of oxido-redox stress towards a reductive state and 
will require new robust models and approaches.  
 
Although the mechanisms that cause and regulate reductive stress are elusive, a number of 
factors have been implicated including activation of nuclear erythroid-2 like factor-2 (Nrf2), heat 
shock protein (HSP), reactive oxygen species and glucose 6 phosphate dehydrogenase (G6PD) (14). 
In addition regulation of ROS scavenging by antioxidants in a compartment-specific manner 
influences redox status. Using targeted viral gene transfer vectors expressing redox-sensitive GFP 
fused to sensor domains to measure oxidized glutathione or H2O2 in cultured H9c2 cardiomyocytes, it 
was found that antioxidant flux is dependent on mitochondrial substrate catabolism and the 
mitochondrial thioredoxin- and glutathione-driven antioxidant network (15). The H9c2 model also 
revealed that ROS scavenging by mitochondrial antioxidants influences ROS regulation in the 
cytoplasmic compartment, similar to what was revealed in the cardiac myocyte-specific Grx1-roGFP2 
sensor mice (4), thus supporting the notion of redox interplay between mitochondrial and cytoplasmic 
subcellular compartments.  
 
 While the field of reductive stress is still immature, the novel findings reported in the current 
issue of the journal (4) highlight the importance of both extremes of redox balance in ischaemic 
cardiac injury with clear evidence that oxidative and reductive stress in a subcellular compartment-
specific manner play a role in redox control of the heart. What still remains unclear however is 
whether the damage induced by both forms of redox stress is oxidative in character. Unfortunately in 
the study under discussion, this was not interrogated with reactive oxygen species scavengers, such as 
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N-acetyl cysteine, tempol or tiron, Another drawback of the study is that the glutathione redox 
potential was only examined in the mitochondrial and cytoplasmic domains of cardiomyocytes, 
ignoring the potentially important contribution of oxido-reductive stress in other organelles such as 
the endoplasmic reticulum, especially in relation to the unfolded protein response (endoplasmic 
reticular stress) associated with cardiac injury. Despite these limitations, Swain et al (4) have 
advanced the field, not only by adding a new biosensor model to the toolbox of redox probes, but by 
demonstrating that there is a complex cooperative redox network that impacts redox stress in cardiac 
health and disease. Reductive stress appears to be as important as oxidative stress in ischemic cardiac 
injury. As the field matures, the exact interplay between oxido-reductive stress will become more 
evident.  
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Figure legend 
 
Schematic demonstrating the interplay between processes that cause oxidative and reductive 
stress in cardiomyocytes. Cardiac stressors, such as ischemia, hypoxia, reactive oxygen species 
(ROS), vasoactive agents, induces ROS generation through mitochondrial and NADPH oxidase 
sources. In addition, these stimuli activate mitochondrial anti-oxidant systems and increased 
generation of reducing equivalents. Redox processes are tightly regulated in subcellular 
compartments, including the mitochondria and cytoplasm where ROS influence distinct 
signaling pathways. These processes may be modulated by the state of oxido-reductive stress. 
The role of endoplasmic reticular (ER) stress is unclear in this paradigm. Ang II, angiotensin II; 
GSH, reduced glutathione; GSSG, glutathione disulfide; GPX, glutathione peroxidase; GSR. 
Glutathione reductase; G6PD, glucose-6-phosphate dehydrogenase; SOD, superoxide 
dismutase. 
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